Now showing items 807-826 of 3281

    • Distortion correction of echo-planar diffusion-weighted images of uterine cervix. 

      deSouza, NM; Orton, M; Downey, K; Morgan, VA; Collins, DJ; Giles, SL; Payne, GS (2016-05)
      To investigate the clinical utility of the reverse gradient algorithm in correcting distortions in diffusion-weighted images of the cervix and for increasing diagnostic performance.Forty-one patients ages 25-72 years (mean ...
    • Distress, the 6(th) vital sign in cancer care Caring for patients’ emotional needs: what does this mean and what helps? 

      Watson, M; Bultz, BD (SPRINGER, 2010-09)
      Distress has been endorsed as the 6(th) Vital Sign by the International Psycho-Oncology Society (IPOS) in 2009 with Screening for Distress as a proposed IPOS strategy in 2010. The need for skilled psychological care is ...
    • Distributions of scatter-to-primary and signal-to-noise ratios per pixel in digital chest imaging 

      Ullman, G; Sandborg, M; Dance, DR; Hunt, R; Carlsson, GA (OXFORD UNIV PRESS, 2005)
      The aim of this work was to calculate distributions of scatter-to-primary ratios (epsilon(s)/epsilon(p)) and signal-to-noise ratios per pixel (SNRp) in chest images. Such distributions may provide useful information on how ...
    • Divergent adaptation in thyroid cancers. 

      Sottoriva, A (2018-06-01)
    • Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. 

      Weigelt, B; Comino-Méndez, I; de Bruijn, I; Tian, L; Meisel, JL; García-Murillas, I; Fribbens, C; Cutts, R; Martelotto, LG; Ng, CKY; Lim, RS; Selenica, P; Piscuoglio, S; Aghajanian, C; Norton, L; Murali, R; Hyman, DM; Borsu, L; Arcila, ME; Konner, J; Reis-Filho, JS; Greenberg, RA; Robson, ME; Turner, NC (2017-11-01)
      Purpose: Resistance to platinum-based chemotherapy or PARP inhibition in germline BRCA1 or BRCA2 mutation carriers may occur through somatic reversion mutations or intragenic deletions that restore BRCA1 or BRCA2 function. ...
    • The Diversification of Cell Death and Immunity: Memento Mori. 

      Legrand, AJ; Konstantinou, M; Goode, EF; Meier, P (2019-10-17)
      Why do cells have so many ways to die? Why does "cellular suicide" exist at all? In the war against pathogens and rogue cells, organisms developed cellular suicide as a last resort. Fighting an evolutionary arms race, cell ...
    • ‘Dividing the desolation’: Clients views on the benefits of a cancer counselling service 

      Boulton, M; Boudioni, M; Mossman, J; Moynihan, G; Leydon, G; Ramirez, A
      This paper describes clients’ accounts of the benefits they derived from a short course of cancer counselling provided within a humanist framework. Three hundred and two clients who had attended at least one session of a ...
    • DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver 

      Mei, N; Arlt, VM; Phillips, DH; Heflich, RH; Chen, T (ELSEVIER SCIENCE BV, 2006-12-01)
      Aristolochic acid (AA) is a potent nephrotoxin and carcinogen and is the causative factor for Chinese herb nephropathy. AA has been associated with the development of urothelial cancer in humans, and kidney and forestomach ...
    • DNA adducts and cancer risk in prospective studies: a pooled analysis and a meta-analysis 

      Veglia, F; Loft, S; Matullo, G; Peluso, M; Munnia, A; Perera, F; Phillips, DH; Tang, D; Autrup, H; Raaschou-Nielsen, O; Tjonneland, A; Vineis, P; Invest, GEPIC (OXFORD UNIV PRESS, 2008-05)
      Bulky DNA adducts are biomarkers of exposure to aromatic compounds and of the ability of the individual to metabolically activate carcinogens and to repair DNA damage. Their ability to predict cancer onset is uncertain. ...
    • DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. 

      Lord, GM; Hollstein, M; Arlt, VM; Roufosse, C; Pusey, CD; Cook, T; Schmeiser, HH (2004-04)
      BACKGROUND: Aristolochic acid-associated nephropathy (AAN) is a specific type of renal disease that predisposes patients to a high risk of urothelial carcinoma. The authors have analyzed DNA from a patient who had urothelial ...
    • DNA adducts as markers of exposure and risk 

      Phillips, DH (2005)
      Many carcinogens exert their biological effects through the formation of DNA adducts by metabolically activated intermediates. Detecting the presence of DNA adducts in human tissues is, therefore, a tool for molecular ...
    • DNA Copy Number Aberrations, and Human Papillomavirus Status in Penile Carcinoma. Clinico-Pathological Correlations and Potential Driver Genes 

      Lambros, Maryou (2016)
      Penile squamous cell carcinoma is a rare disease, in which somatic genetic aberrations have yet to be characterized. We hypothesized that gene copy aberrations might correlate with human papillomavirus status and ...
    • DNA Damage Activates a Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA Stabilization 

      Reinhardt, HC; Hasskamp, P; Schmedding, I; Morandell, S; van Vugt, MATM; Wang, X; Linding, R; Ong, S-E; Weaver, D; Carr, SA; Yaffe, MB (CELL PRESS, 2010-10-08)
      Following genotoxic stress, cells activate a complex kinase-based signaling network to arrest the cell cycle and initiate DNA repair. p53-defective tumor cells rewire their checkpoint response and become dependent on the ...
    • DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression. 

      Barr, AR; Cooper, S; Heldt, FS; Butera, F; Stoy, H; Mansfeld, J; Novák, B; Bakal, C (2017-03-20)
      Following DNA damage caused by exogenous sources, such as ionizing radiation, the tumour suppressor p53 mediates cell cycle arrest via expression of the CDK inhibitor, p21. However, the role of p21 in maintaining genomic ...
    • DNA Damage, Repair, and Cancer Metabolism. 

      Turgeon, M-O; Perry, NJS; Poulogiannis, G (2018)
      Although there has been a renewed interest in the field of cancer metabolism in the last decade, the link between metabolism and DNA damage/DNA repair in cancer has yet to be appreciably explored. In this review, we examine ...
    • DNA fragmentation based combinatorial approaches to soluble protein expression Part II: Library expression, screening and scale-up 

      Savva, R; Prodromou, C; Driscoll, PC (ELSEVIER SCI LTD, 2007-11)
      In this second of a two-part review encompassing random, combinatorial methods for soluble protein ‘domain hunting’, we focus upon the expression screening from DNA fragment libraries. Given a library of domain length-encoding ...
    • DNA fragmentation-based combinatorial approaches to soluble protein expression Part I. Generating DNA fragment libraries 

      Prodromou, C; Sawa, R; Driscoll, PC (ELSEVIER SCI LTD, 2007-11)
      In addressing a new drug discovery target, the generation of tractable protein substrates for functional and structural analyses can represent a significant hurdle. Traditional approaches rely on protein expression trials ...
    • DNA methylation-based classification of central nervous system tumours. 

      Capper, D; Jones, DTW; Sill, M; Hovestadt, V; Schrimpf, D; Sturm, D; Koelsche, C; Sahm, F; Chavez, L; Reuss, DE; Kratz, A; Wefers, AK; Huang, K; Pajtler, KW; Schweizer, L; Stichel, D; Olar, A; Engel, NW; Lindenberg, K; Harter, PN; Braczynski, AK; Plate, KH; Dohmen, H; Garvalov, BK; Coras, R; Hölsken, A; Hewer, E; Bewerunge-Hudler, M; Schick, M; Fischer, R; Beschorner, R; Schittenhelm, J; Staszewski, O; Wani, K; Varlet, P; Pages, M; Temming, P; Lohmann, D; Selt, F; Witt, H; Milde, T; Witt, O; Aronica, E; Giangaspero, F; Rushing, E; Scheurlen, W; Geisenberger, C; Rodriguez, FJ; Becker, A; Preusser, M; Haberler, C; Bjerkvig, R; Cryan, J; Farrell, M; Deckert, M; Hench, J; Frank, S; Serrano, J; Kannan, K; Tsirigos, A; Brück, W; Hofer, S; Brehmer, S; Seiz-Rosenhagen, M; Hänggi, D; Hans, V; Rozsnoki, S; Hansford, JR; Kohlhof, P; Kristensen, BW; Lechner, M; Lopes, B; Mawrin, C; Ketter, R; Kulozik, A; Khatib, Z; Heppner, F; Koch, A; Jouvet, A; Keohane, C; Mühleisen, H; Mueller, W; Pohl, U; Prinz, M; Benner, A; Zapatka, M; Gottardo, NG; Driever, PH; Kramm, CM; Müller, HL; Rutkowski, S; von Hoff, K; Frühwald, MC; Gnekow, A; Fleischhack, G; Tippelt, S; Calaminus, G; Monoranu, C-M; Perry, A; Jones, C; Jacques, TS; Radlwimmer, B; Gessi, M; Pietsch, T; Schramm, J; Schackert, G; Westphal, M; Reifenberger, G; Wesseling, P; Weller, M; Collins, VP; Blümcke, I; Bendszus, M; Debus, J; Huang, A; Jabado, N; Northcott, PA; Paulus, W; Gajjar, A; Robinson, GW; Taylor, MD; Jaunmuktane, Z; Ryzhova, M; Platten, M; Unterberg, A; Wick, W; Karajannis, MA; Mittelbronn, M; Acker, T; Hartmann, C; Aldape, K; Schüller, U; Buslei, R; Lichter, P; Kool, M; Herold-Mende, C; Ellison, DW; Hasselblatt, M; Snuderl, M; Brandner, S; Korshunov, A; von Deimling, A; Pfister, SM (2018-03-22)
      Accurate pathological diagnosis is crucial for optimal management of patients with cancer. For the approximately 100 known tumour types of the central nervous system, standardization of the diagnostic process has been shown ...
    • DNA minor-groove recognition by small molecules 

      Neidle, S (ROYAL SOC CHEMISTRY, 2001)
    • DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. 

      Touat, M; Sourisseau, T; Dorvault, N; Chabanon, RM; Garrido, M; Morel, D; Krastev, DB; Bigot, L; Adam, J; Frankum, JR; Durand, S; Pontoizeau, C; Souquère, S; Kuo, M-S; Sauvaigo, S; Mardakheh, F; Sarasin, A; Olaussen, KA; Friboulet, L; Bouillaud, F; Pierron, G; Ashworth, A; Lombès, A; Lord, CJ; Soria, J-C; Postel-Vinay, S (2018-04-02)
      Synthetic lethality is an efficient mechanism-based approach to selectively target DNA repair defects. Excision repair cross-complementation group 1 (ERCC1) deficiency is frequently found in non-small-cell lung cancer ...